• Clinigen acquires its first product, Foscavir and commences Global Access Programs supplying unlicensed medicines globally
  • Employees: 32


  • Clinigen recognised as the fastest-growing private company in the UK by the Sunday Times Virgin Fast Track 100
  • Employees: 48


  • Clinigen moves warehousing into brand new Operations Centre
  • Clinigen lists on the Alternative Investment Market (AIM) of the London Stock Exchange – the first UK healthcare company to list in London in five years
  • Employees: 72


  • Clinigen marks its first year as a public company by winning Best Newcomer at the London Stock Exchange AIM Awards
  • Clinigen wins IPO of the Year at the 2013 M&A Awards
  • Clinigen SP acquires its second product, Cardioxane
  • Employees: 101


  • Clinigen opens new, extended headquarters in Burton-on-Trent, UK
  • Clinigen acquires its third product, Savene
  • Clinigen acquires its fourth product, Ethyol
  • Clinigen launches its new web portal, Cliniport, which allows healthcare professionals to order products directly via the internet
  • Employees: 116


  • Clinigen acquires Idis in April 2015 to become the global leader in providing ethical compliant access to unlicensed medicines
  • Clinigen acquires Link Healthcare in October 2015 to expand its ability to provide access to medicines for patients in the Africa, Asia and Australia regions
  • Clinigen awarded the ServiceMark accreditation by The Institute of Customer Service, in recognition of the Group’s commitment to, and achievement in, customer services
  • Employees: 450


  • Launch of Japanese business, Clinigen KK, with Foscavir as its first product
  • Clinigen acquires its fifth product, Totect US, completing the global dexrazoxane portfolio
  • Clinigen continues Foscavir development with purchase of a new bag presentation
  • Clinigen launches Ethyol in the US in partnership with Cumberland Pharma
  • Employees: 530


  • Clinigen receives investors in people silver award
  • Clinigen receives EC approval for updates to Cardioxane product information
  • Clinigen launched Totect in the US in partnership with Cumberland Pharma
  • Clinigen acquires IMMC, Japan’s largest supplier of unlicensed medicines
  • Clinigen acquires Quantum Pharma plc in November 2017 extending its Unlicensed Medicines capability and accelerating its unlicensed to licensed global strategy
  • Employees: 849


  • Clinigen signs extended partnership agreement with Bristol-Myers Squibb to supply its portfolio of products in South Africa
  • Clinigen acquires its sixth product, Proleukin (global rights outside the US)
  • Clinigen acquires its seventh product, Imukin (global rights outside the US, Canada and Japan)
  • Clinigen acquires CSM a specialist provider of packaging, labelling, warehousing and distribution services with infrastructure in the US, Belgium and Germany
  • Clinigen acquires iQone, a Swiss-based specialty pharmaceutical business providing EU medical scientific liaison (MSL) capability
  • Employees: 1,182


  • Clinigen acquires the US rights to Proleukin
  • Clinigen Direct is a globally available service which helps clinicians, pharmacists and pharmacy technicians source hard to find medicines by connecting them with our specialist customer services team, either online or by phone (and even fax).


  • Clinigen signs exclusive global licensing and distribution agreement to commercialise Erwinase
  • Clinigen and GC Pharma collaboratively submit New Drug Application for Hunterase (Idursulfase-beta) ICV in Japan
  • Clinigen expands footprint in Southeast Asia with opening of new Malaysia office


  • Launched Hunterase in Japan and begin roll-out of Erwinase in licenced and unlicenced markets. COVID-19 headwinds impact demand for Proleukin and On-Demand. Divestment of UK Specials and Aseptics business
  • As announced in the half year results, from 1 January 2021, the Group structure was simplified, moving from three divisions to two: Services and Products. This change better reflects the alignment of the Group’s activities to its end customers: pharmaceutical clients and healthcare professionals


  • Clinigen acquired by international private equity company Triton.
  • Acquired US based Pharmacoviglinece business - Drug Safety Navigator